000293958 001__ 293958
000293958 005__ 20241113132433.0
000293958 0247_ $$2doi$$a10.1186/s12916-024-03671-x
000293958 0247_ $$2pmid$$apmid:39379960
000293958 0247_ $$2altmetric$$aaltmetric:169106398
000293958 037__ $$aDKFZ-2024-02023
000293958 041__ $$aEnglish
000293958 082__ $$a610
000293958 1001_ $$aZimmer, Philipp$$b0
000293958 245__ $$aPhysical activity levels are positively related to progression-free survival and reduced adverse events in advanced ER+ breast cancer.
000293958 260__ $$aHeidelberg [u.a.]$$bSpringer$$c2024
000293958 3367_ $$2DRIVER$$aarticle
000293958 3367_ $$2DataCite$$aOutput Types/Journal article
000293958 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1728466655_19573
000293958 3367_ $$2BibTeX$$aARTICLE
000293958 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000293958 3367_ $$00$$2EndNote$$aJournal Article
000293958 520__ $$aIncreased levels of physical activity are associated with a reduction of breast cancer mortality, especially in postmenopausal women with positive hormone receptor status. So far, previous observational case-control and cohort studies have focused on associations between overall leisure time physical activity and survival of women with breast cancer in general.In this multicenter prospective cohort study, conducted in Germany between 30th August 2012 to 29th December 2017, we investigated general physical activity in a homogenous sample of n = 1440 postmenopausal women with advanced (inoperable locally advanced or metastatic), hormone receptor-positive breast cancer receiving the same therapy (everolimus and exemestane). Self-reported physical activity was assessed using the Godin Leisure Time Exercise Questionnaire (GLTEQ) before and every 3 months during treatment. Participants were then classified into 'active' and 'insufficiently active' to screen their activity behavior the week prior to medical treatment. In addition, changes in physical activity patterns were assessed. Adjusted Cox regression analyses were performed for the activity categories to determine hazard ratios (HR). Besides progression-free survival (PFS), adverse events (AEs), QoL, and fatigue were assessed every 3 months until study termination.Compared to 'insufficiently active' patients, 'active' individuals indicated a significantly longer PFS (HR: 0.84 [0.74; 0.984], p = .0295). No significant differences were observed for changes of physical activity behavior. Patients who reported to be 'active' at baseline revealed significantly fewer AEs compared to 'insufficiently' active patients. In detail, both severe and non-severe AEs occurred less frequently in the 'active' patients group. In line with that, QoL and fatigue were better in physical 'active' patients compared to their insufficient active counterparts at the last post-baseline assessment. Participants who remained or become active indicated less AEs, a higher QoL, and reduced fatigue levels.Physical activity behavior prior to medical treatment might have prognostic value in patients with advanced breast cancer in terms of extending the PFS. Moreover, physical activity before and during treatment may reduce treatment-related side effects and improve patients' QoL and fatigue.EUPAS9462. Registered 30th October 2012 'retrospectively registered.'
000293958 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000293958 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000293958 650_7 $$2Other$$aAdverse events
000293958 650_7 $$2Other$$aBreast cancer
000293958 650_7 $$2Other$$aExercise
000293958 650_7 $$2Other$$aFatigue
000293958 650_7 $$2Other$$aPhysical activity
000293958 650_7 $$2Other$$aQuality of life
000293958 650_7 $$2Other$$aSurvival
000293958 7001_ $$aEsser, Tobias$$b1
000293958 7001_ $$aLueftner, Diana$$b2
000293958 7001_ $$aSchuetz, Florian$$b3
000293958 7001_ $$aBaumann, Freerk T$$b4
000293958 7001_ $$aRody, Achim$$b5
000293958 7001_ $$aSchneeweiss, Andreas$$b6
000293958 7001_ $$aHartkopf, Andreas D$$b7
000293958 7001_ $$aDecker, Thomas$$b8
000293958 7001_ $$aUleer, Christoph$$b9
000293958 7001_ $$aStoetzer, Oliver J$$b10
000293958 7001_ $$aFoerster, Frank$$b11
000293958 7001_ $$aSchmidt, Marcus$$b12
000293958 7001_ $$aMundhenke, Christoph$$b13
000293958 7001_ $$0P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aSteindorf, Karen$$b14$$udkfz
000293958 7001_ $$aTesch, Hans$$b15
000293958 7001_ $$aJackisch, Christian$$b16
000293958 7001_ $$aFischer, Thomas$$b17
000293958 7001_ $$aHanson, Sven$$b18
000293958 7001_ $$aKreuzeder, Julia$$b19
000293958 7001_ $$aGuderian, Gernot$$b20
000293958 7001_ $$aFasching, Peter A$$b21
000293958 7001_ $$aBloch, Wilhelm$$b22
000293958 773__ $$0PERI:(DE-600)2131669-7$$a10.1186/s12916-024-03671-x$$gVol. 22, no. 1, p. 442$$n1$$p442$$tBMC medicine$$v22$$x1741-7015$$y2024
000293958 8564_ $$uhttps://inrepo02.dkfz.de/record/293958/files/s12916-024-03671-x.pdf
000293958 8564_ $$uhttps://inrepo02.dkfz.de/record/293958/files/s12916-024-03671-x.pdf?subformat=pdfa$$xpdfa
000293958 909CO $$ooai:inrepo02.dkfz.de:293958$$pVDB
000293958 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000293958 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000293958 9141_ $$y2024
000293958 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBMC MED : 2022$$d2023-10-25
000293958 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-25
000293958 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-25
000293958 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-25
000293958 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-05-02T09:07:15Z
000293958 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-05-02T09:07:15Z
000293958 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Open peer review$$d2023-05-02T09:07:15Z
000293958 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-25
000293958 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-25
000293958 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-25
000293958 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-25
000293958 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-25
000293958 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-25
000293958 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-25
000293958 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-25
000293958 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-25
000293958 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBMC MED : 2022$$d2023-10-25
000293958 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-10-25
000293958 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-10-25
000293958 9201_ $$0I:(DE-He78)C110-20160331$$kC110$$lBewegung, Präventionsforschung und Krebs$$x0
000293958 980__ $$ajournal
000293958 980__ $$aVDB
000293958 980__ $$aI:(DE-He78)C110-20160331
000293958 980__ $$aUNRESTRICTED